Artiva Biotherapeutics (ARTV) Total Current Liabilities (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Total Current Liabilities data on file, last reported at $10.9 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $10.9 million, down 10.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.9 million (down 10.85% YoY), and the FY2025 annual result was $13.1 million, up 6.81% from the prior year.
• Total Current Liabilities fell to $10.9 million in Q1 2026 per ARTV's latest filing, from $13.1 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $13.3 million in Q3 2024 and troughed at $10.8 million in Q2 2025.
• A 4-year average of $11.9 million and a median of $12.2 million in 2025 frame the typical range for Total Current Liabilities.
• On a YoY basis, Total Current Liabilities climbed as much as 6.81% in 2025 and fell as far as 16.35% in 2025.
• A 4-year view of Total Current Liabilities shows it stood at $12.2 million in 2023, then grew by 0.21% to $12.3 million in 2024, then rose by 6.81% to $13.1 million in 2025, then decreased by 16.86% to $10.9 million in 2026.
• Business Quant data shows ARTV's Total Current Liabilities at $10.9 million in Q1 2026, $13.1 million in Q4 2025, and $11.1 million in Q3 2025.